CN100338042C - 作为环加氧酶(cox)抑制剂的三唑衍生物 - Google Patents

作为环加氧酶(cox)抑制剂的三唑衍生物 Download PDF

Info

Publication number
CN100338042C
CN100338042C CNB028269004A CN02826900A CN100338042C CN 100338042 C CN100338042 C CN 100338042C CN B028269004 A CNB028269004 A CN B028269004A CN 02826900 A CN02826900 A CN 02826900A CN 100338042 C CN100338042 C CN 100338042C
Authority
CN
China
Prior art keywords
compound
salt
phenyl
methoxy
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028269004A
Other languages
English (en)
Chinese (zh)
Other versions
CN1612865A (zh
Inventor
青木敏
中川俊哉
小西信清
中村克哉
大森浩喜
洼田有克
桥本典夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd, Astellas Pharma Inc filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CN1612865A publication Critical patent/CN1612865A/zh
Application granted granted Critical
Publication of CN100338042C publication Critical patent/CN100338042C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB028269004A 2001-11-09 2002-10-30 作为环加氧酶(cox)抑制剂的三唑衍生物 Expired - Fee Related CN100338042C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR8782 2001-11-09
AUPR8782A AUPR878201A0 (en) 2001-11-09 2001-11-09 New compounds

Publications (2)

Publication Number Publication Date
CN1612865A CN1612865A (zh) 2005-05-04
CN100338042C true CN100338042C (zh) 2007-09-19

Family

ID=3832601

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028269004A Expired - Fee Related CN100338042C (zh) 2001-11-09 2002-10-30 作为环加氧酶(cox)抑制剂的三唑衍生物

Country Status (15)

Country Link
US (1) US6927230B2 (enExample)
EP (1) EP1442026B9 (enExample)
JP (2) JP3972208B2 (enExample)
KR (1) KR100511884B1 (enExample)
CN (1) CN100338042C (enExample)
AR (1) AR037347A1 (enExample)
AT (1) ATE427940T1 (enExample)
AU (1) AUPR878201A0 (enExample)
CA (1) CA2465757C (enExample)
DE (1) DE60231897D1 (enExample)
DK (1) DK1442026T3 (enExample)
ES (1) ES2325318T3 (enExample)
PT (1) PT1442026E (enExample)
TW (1) TWI300713B (enExample)
WO (1) WO2003040110A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2433623A1 (en) * 2001-01-02 2002-07-18 Fujisawa Pharmaceutical Co., Ltd. Pyridine derivatives useful as cyclooxygenase inhibitor
AUPR878201A0 (en) * 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
KR100470076B1 (ko) * 2002-11-27 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
NZ540515A (en) 2002-12-02 2008-01-31 Astellas Pharma Inc Pyrazole derivatives useful as COX-I inhibitors
WO2004060367A1 (en) * 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Imidazole and triazole derivatives useful as selective cox-1 inhibitors
CA2515119A1 (en) 2003-02-07 2004-08-19 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
JP2006525320A (ja) * 2003-05-08 2006-11-09 アステラス製薬株式会社 Ｃｏｘ阻害剤
EP1803719A4 (en) * 2004-10-19 2008-07-02 Daiichi Seiyaku Co 1,5-DIHETEROCYCLUS-1H-triazole
RU2010144554A (ru) 2008-04-01 2012-05-10 Астеллас Фарма Инк. (Jp) Средство для предотвращения и/или лечения сосудистых заболеваний
WO2011152297A1 (ja) * 2010-05-31 2011-12-08 アステラス製薬株式会社 トリアゾール化合物の固体分散体
UA112418C2 (uk) * 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
KR101178947B1 (ko) * 2011-04-29 2012-09-03 한국생명공학연구원 올레아놀린산 아세테이트를 유효성분으로 포함하는 ｔｌｒ 및 ｉｌ-6 매개성 질환 예방 또는 치료용 약학적 조성물
WO2012170839A2 (en) * 2011-06-09 2012-12-13 Cardeus Pharmaceuticals, Inc. Treatment of neuroinflammatory disease with selective cox1 inhibitors
MX2015005744A (es) 2012-11-09 2016-02-10 Univ Cornell Inhibidores de malti de molecula pequeña.
MX2021005801A (es) 2018-11-20 2021-08-05 Sparrow Pharmaceuticals Inc Metodos para administrar corticosteroides.
CN115611901B (zh) * 2021-07-16 2024-04-30 华南理工大学 一种氮杂䓬类化合物或其药学上可接受的盐及其制备方法和应用
IL316907A (en) 2022-05-16 2025-01-01 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0155486A1 (de) * 1984-02-07 1985-09-25 ALKALOIDA VEGYéSZETI GYáR 1,3,5-Trisubstituierte 1,2,4-Triazolderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0157259A1 (de) * 1984-03-16 1985-10-09 Ciba-Geigy Ag 3-Mercapto-1,2,4-triazacycloalkadienderivate
EP0162217A1 (de) * 1984-03-16 1985-11-27 Ciba-Geigy Ag 1,2,4-Triazacycloalkadienderivate
WO2000010563A1 (en) * 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0051084A1 (en) 1980-11-04 1982-05-12 American Cyanamid Company Substituted 1H-1,2,4-triazoles
EP0159018A3 (en) 1984-04-17 1986-10-01 HENKEL CORPORATION (a Delaware corp.) Production of d-alpha-tocopherol from natural plant sources
JPS60233066A (ja) * 1984-05-07 1985-11-19 Nippon Nohyaku Co Ltd １．５−ジフエニルトリアゾ−ル誘導体及びその製造方法
EP1068187A1 (en) 1998-04-08 2001-01-17 Abbott Laboratories Pyrazole inhibitors of cytokine production
EP1099695A1 (en) 1999-11-09 2001-05-16 Laboratoire Theramex S.A. 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
AUPR878201A0 (en) * 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0155486A1 (de) * 1984-02-07 1985-09-25 ALKALOIDA VEGYéSZETI GYáR 1,3,5-Trisubstituierte 1,2,4-Triazolderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0157259A1 (de) * 1984-03-16 1985-10-09 Ciba-Geigy Ag 3-Mercapto-1,2,4-triazacycloalkadienderivate
EP0162217A1 (de) * 1984-03-16 1985-11-27 Ciba-Geigy Ag 1,2,4-Triazacycloalkadienderivate
WO2000010563A1 (en) * 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds

Also Published As

Publication number Publication date
CN1612865A (zh) 2005-05-04
WO2003040110A1 (en) 2003-05-15
CA2465757C (en) 2011-11-29
EP1442026A1 (en) 2004-08-04
DK1442026T3 (da) 2009-07-06
ATE427940T1 (de) 2009-04-15
JP2007169290A (ja) 2007-07-05
AUPR878201A0 (en) 2001-12-06
TWI300713B (en) 2008-09-11
CA2465757A1 (en) 2003-05-15
PT1442026E (pt) 2009-06-25
JP2004521964A (ja) 2004-07-22
KR20030060878A (ko) 2003-07-16
US20030191155A1 (en) 2003-10-09
EP1442026B1 (en) 2009-04-08
US6927230B2 (en) 2005-08-09
KR100511884B1 (ko) 2005-09-05
ES2325318T3 (es) 2009-09-01
JP3972208B2 (ja) 2007-09-05
DE60231897D1 (de) 2009-05-20
AR037347A1 (es) 2004-11-03
EP1442026B9 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
CN100338042C (zh) 作为环加氧酶(cox)抑制剂的三唑衍生物
CN1310921C (zh) 双环氧代吡啶和氧代嘧啶衍生物
CN1198807C (zh) 作为环加氧酶－2抑制剂的5－芳基－1h－1,2,4－三唑化合物及含有它们的药物组合物
CN1221262C (zh) 治疗炎性疾病的酞嗪衍生物
CN1158281C (zh) 作为iv型磷酸二酯酶抑制剂的1-芳基-1,8-二氮杂萘-4-酮衍生物
CN1050126C (zh) 三取代咪唑类化合物、其制备方法与用途以及含有它们的药物组合物
CN1319950C (zh) 3－取代的－4－嘧啶酮衍生物
CN1259942A (zh) 作为因子Xa抑制剂的新的胍模拟物
CN1191239C (zh) 用于治疗病毒性疾病的吡唑衍生物
CN1289326A (zh) 用于治疗局部缺血的n－[(取代的五元二氮杂或三氮杂二不饱和环)羰基]胍衍生物
CN1747949A (zh) 无环吡唑化合物
CN1420889A (zh) 具有药物活性的二氢异吲哚衍生物
CN1378537A (zh) 嘧啶衍生物
CN1070404A (zh) 新的杂环衍生物
CN1119856A (zh) Hiv逆转录酶抑制剂
CN1213307A (zh) 新的取代的咪唑化合物
CN1312807A (zh) 糖元合成酶激酶3的抑制剂
CN1791410A (zh) 通过抑制jnk治疗或预防炎性或代谢性病症的方法
CN1856307A (zh) 喹啉钾通道抑制剂
CN1070173C (zh) 用作药物的苯甲酰基胍衍生物
CN1675189A (zh) 苯并噻唑衍生物的新用途
CN1127486C (zh) 二氮杂萘衍生物磷酸二酯酶4抑制剂
HK1052701A1 (zh) 作为抗炎/镇痛剂的杂环-烷基磺酰基吡唑衍生物
CN100351237C (zh) 杂环化合物及其制备方法和含该化合物的药物组合物以及其在医药中的用途
CN1826111A (zh) 用于治疗变应性和过增生性疾病的咪唑衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ASTELLAS PHARMA INC.

Free format text: FORMER OWNER: FUJISAWA PHARMACEUTICAL CO., LTD.

Effective date: 20060407

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20060407

Address after: Tokyo, Japan

Applicant after: Yamanouchi Pharma Co., Ltd.

Address before: Osaka City, Osaka of Japan

Applicant before: Fujisawa Pharmaceutical Co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070919

Termination date: 20141030

EXPY Termination of patent right or utility model